Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?
Saved in:
| Title: | Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients? |
|---|---|
| Authors: | Awidi M; Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: Muhammad.awidi@roswellpark.org., Mier-Hicks A; Texas Oncology, Dallas, TX., Perimbeti S; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Attwood K; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Chen H; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Jain P; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Yau E; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Early A; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Dy GK; Roswell Park Comprehensive Cancer Center, Buffalo, NY. |
| Source: | Clinical lung cancer [Clin Lung Cancer] 2024 Sep; Vol. 25 (6), pp. 509-518. Date of Electronic Publication: 2024 May 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
